Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

Patients with psoriatic arthritis treated with secukinumab demonstrated early and sustained resolution of enthesitis, with 300 mg doses providing higher resolution than 150 mg in more severe cases, ...

The severity of enthesitis in psoriatic arthritis is a potential marker for severe disease and joint damage, a cross-sectional study found. For instance, a 10-unit increase on the Madrid Sonographic ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA. The Food and Drug ...

Around 5% of patients treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis experience musculoskeletal (MSK) symptoms, according to the results of a descriptive study. The main ...

Patients with hidradenitis suppurativa (HS) may have subclinical spondyloarthritis (SpA) features, e.g., sacroiliitis and ...

Credit: Getty Images. The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis. Novartis announced results from a phase 3b ...

In this cross-sectional study, Poggenborg and colleagues evaluated the ability of an emerging imaging technology, "whole-body" MRI (WBMRI), to detect enthesitis in patients with psoriatic arthritis ...

Ultrasound assessment of enthesitis can effectively distinguish patients with vs without SpA, with inflammatory B-mode lesions serving as the strongest independent marker.

Basel, December 22, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) for the treatment ...

New approvals are based on JUNIPERA trial data showing Cosentyx (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both ...